Early Psychosis, Schizophrenia Prodromal
Conditions
Brief summary
The goal of this observational study is to investigate the early sensory system in clinical high risk (CHR), first episode psychosis (FEP) individuals and heathly controls. The main questions it aims to answer are: * Can anomalies in visual and auditory sensory processing serve as early markers of psychosis risk? * How are these sensory anomalies related to clinical symptom severity and emotional recognition deficits? Researchers will compare CHR and PEP participants to healthy controls to see if sensory processing differences can help identify individuals at higher risk of developing psychosis. Participants will: * Complete behavioral tasks evaluating visual processing (contrast sensitivity, contour integration, facial emotion recognition, visual inference using Necker cubes) and auditory processing (tone-matching, auditory emotion recognition). A temporal perception component will also be assessed within the auditory and emotion recognition tasks, rather than as a separate task. * Undergo electrophysiological assessments of retinal function using flash stimulation to record retinal potentials (a-wave, b-wave, phNR, oscillatory potentials). * Provide demographic, clinical, and neuropsychological data during study visits. * For CHR participants, attend follow-up visits up to 6 months post initial assessments to evaluate psychotic symptom progression.
Interventions
BEHAVIORALbehavioral tasks
All participants will undergo behavioral assessments of visual and auditory processing, including contrast sensitivity, facial emotion recognition, visual inference using Necker cubes, tone-matching, and auditory emotion recognition.
DEVICEElectroretinography
Participants will additionally undergo electrophysiological recordings of retinal function (a-wave, b-wave, phNR, oscillatory potentials) using flash stimulation.
DIAGNOSTIC_TESTComprehensive Assessment of At Risk Mental States (CAARMS)
All participants will be assessed using the CAARMS in order to evaluate their symptoms and classify them into either the CHR or FEP group
BEHAVIORALNeuropsychological tests
TAP attention and working memory test, fNART, VOSP, Verbal fluency test.
Sponsors
Centre Psychothérapique de Nancy
Institut National de la Santé Et de la Recherche Médicale, France
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
Yes
Inclusion criteria
All groups: * Age between 18 and 30 years * Normal or corrected-to-normal visual acuity * Affiliated with or dependent on a social security health insurance plan * Provided informed consent and co-signed the study consent form with the investigator * Proficient in French Control group (TEM) specific criteria: * No current psychiatric disorder (DSM-IV Axis I), except anxiety disorders * No lifetime history of (hypo)manic episodes or psychotic disorders * No first-degree family history of schizophrenia spectrum disorders * No regular use (more than one month continuously) in the past 6 months of the following medications: benzodiazepines, hypnotics, antidepressants, antipsychotics, mood stabilizers, or psychostimulants Clinical High-Risk (CHR) group specific criteria: -Meet CHR criteria according to CAARMS: Attenuated positive symptoms (APS) below clinical threshold in intensity or frequency OR Brief Limited Intermittent Psychotic Symptoms (SPLI) OR Genetic Risk First-Episode Psychosis (PEP) group specific criteria: -Meet PEP criteria according to CAARMS (psychosis threshold reached)
Exclusion criteria
* Pregnant, postpartum, or breastfeeding women * Individuals deprived of liberty by judicial or administrative decision * Individuals in a life-threatening emergency * Adults under legal protection measures * Adults unable to provide consent and not under legal protection * Impairment that makes participation in the study or understanding of information difficult or impossible * Alcohol dependence (AUDIT score ≥12 for men, ≥11 for women) * Current substance use disorder (DAST score \>6) * Cannabis use disorder (CUDIT-R score ≥13) * History of neurological disorders, including progressive neurological disease * Progressive retinal disease * Chronic glaucoma * Ophthalmologic conditions affecting visual acuity * Current eye infection * Hearing disorders affecting auditory acuity Criteria incompatible with the electroretinographic device: * Presence of photosensitive epilepsy * Allergy to components of the electrode gel * Behavioral problems causing extreme agitation or aggression * Eye or surrounding tissue lesions that may come into contact with the device
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Auditory emotion recognition task | Day 1 for healthy controls, Day 1-30 for patients | Computerized emotion recognition task |
| ERG measure | Day 1 for healthy controls, Day 1-30 for patients | amplitude and latency of the b-wave, a-wave, PhNR and oscillatory potentials |
| Contrast sensitivity task | Day 1 for healthy controls, Day 1-30 for patients | computerized contrast detection task |
| Facial emotion recognition task | Day 1 for healthy controls, Day 1-30 for patients | computerized emotion recognition task |
| Visual inference task | Day 1 for healthy controls, Day 1-30 for patients | Computerized visual inference task |
| Tone matching task | Day 1 for healthy controls, Day 1-30 for patients | Computerized tone matching task |
| CAARMS assessment | Day 1 | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CAARMS assessment | 6 months follow up | Follow-up symptomatic assessment to evaluate the predictive power of sensory treatment (computerized tasks, ERG) for the risk of psychotic transition. |
| TAP Working Memory test | Day 1 | — |
| fNART | Day 1 | — |
| Tap attention test | Day 1 | — |
| Visual Object and Space Perception Battery (VOSP) | Day 1 | — |
| Verbal fluency test | Day 1 | — |
Countries
France
Contacts
CONTACTMélissa FENOT
CONTACTNaoual MELLOUKI BENDIMRED, PhD
PRINCIPAL_INVESTIGATORVincent LAPRÉVOTE, PU.PH
Centre Psychothérapique de Nancy
Outcome results
None listed